Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/8/2025

Initial Treatment Approach for Adenocarcinoma of the Lung

Diagnosis and Staging

  • The European Society for Medical Oncology recommends that the initial treatment approach for patients with adenocarcinoma of the lung should be based on accurate staging, molecular testing, and patient-specific factors, with platinum-based combination chemotherapy being the standard first-line treatment for metastatic disease without actionable mutations 1, 2
  • Adequate tissue sampling is essential for histological diagnosis and molecular testing to guide treatment decisions, according to the American College of Chest Physicians 3
  • Pathological diagnosis should be made according to the WHO classification, with specific subtyping of all NSCLCs necessary for therapeutic decision-making, as recommended by the European Society for Medical Oncology 4
  • Initial evaluation should include a complete history, contrast-enhanced CT scan of the chest and upper abdomen, brain imaging, and PET-CT scan for mediastinal lymph nodes and distant metastasis assessment, as suggested by the European Society for Medical Oncology 4
  • Invasive mediastinal staging is recommended for patients with radiographically normal mediastinum and a central tumor or N1 lymph node enlargement, according to the American College of Chest Physicians 5

Molecular Testing

  • The European Society for Medical Oncology recommends that EGFR mutation status should be systematically analyzed in advanced NSCLC with non-squamous histology 4
  • ALK rearrangement testing should be performed in advanced non-squamous NSCLC, as recommended by the European Society for Medical Oncology 4
  • Testing may focus on never/former light smokers especially in the absence of an activating EGFR mutation or KRAS mutation, according to the European Society for Medical Oncology 1
  • Sufficient tissue should be obtained to allow for molecular testing, which guides treatment decisions, as suggested by the National Comprehensive Cancer Network 6, 3

Treatment Based on Stage

  • The National Comprehensive Cancer Network recommends that surgical resection is preferred for stages I through IIIA non-small cell carcinoma 6
  • A multimodality approach may include surgery, radiotherapy, and chemotherapy for patients with locally advanced disease, as suggested by the National Comprehensive Cancer Network 6
  • Platinum-based combination chemotherapy is the standard first-line treatment for patients with good performance status, according to the European Society for Medical Oncology 2

Special Considerations

  • In the case of solitary brain metastasis, surgical resection followed by whole brain radiotherapy or alternatively radiosurgery with or without WBRT might be beneficial, as suggested by the European Society for Medical Oncology 1
  • For solitary adrenal metastasis, prolonged survival after resection of adrenal and primary tumor has been suggested in selected patients, according to the European Society for Medical Oncology 1

Follow-Up

  • Close follow-up, at least every 6 weeks after first-line therapy, is advised but should depend on individual re-treatment options, as recommended by the European Society for Medical Oncology 1
  • Radiological follow-up should be considered every 6-12 weeks to allow for early initiation of second-line therapy, according to the European Society for Medical Oncology 1

Common Pitfalls to Avoid

  • Inadequate tissue sampling leading to insufficient material for molecular testing, as warned by the American College of Chest Physicians 3
  • Delaying molecular testing, which can impact the timely initiation of targeted therapy, according to the European Society for Medical Oncology 4
  • Not considering re-biopsy at disease progression, which may reveal transformation or new molecular targets, as suggested by the European Society for Medical Oncology 4

Treatment of Adenocarcinoma of the Lung

Initial Evaluation and Molecular Testing

  • The American Thoracic Society recommends testing all adenocarcinomas for EGFR mutations and ALK rearrangements, as these guide first-line therapy decisions, with additional molecular targets including ROS1 rearrangements, MET amplification, RET rearrangements, and BRAF mutations 7

Stage I and II Disease (Early-Stage)

  • The American College of Chest Physicians recommends lobectomy with ipsilateral mediastinal lymph node dissection as the standard surgical approach for early-stage adenocarcinoma of the lung, with pneumonectomy reserved for tumors that cannot be completely resected by lobectomy 8, 9
  • Surgery should be performed by a board-certified thoracic surgeon performing ≥4 anatomic resections monthly, with systematic mediastinal lymph node sampling or complete lymphadenectomy must be performed at resection 9, 10
  • Adjuvant chemotherapy is recommended for stage II disease and has demonstrated survival benefit, according to the National Comprehensive Cancer Network 9, 11

Radiation Therapy Options

  • The American Society for Radiation Oncology recommends stereotactic body radiotherapy (SBRT) as the primary curative-intent approach for patients refusing surgery or deemed inoperable by multidisciplinary team, providing superior local control compared to conventional radiation for medically inoperable stage I patients 9, 10

Stage IV Disease (Metastatic)

  • The National Comprehensive Cancer Network recommends EGFR tyrosine kinase inhibitors (osimertinib, erlotinib, gefitinib, afatinib) as first-line therapy for patients with EGFR mutations, and ALK inhibitors (alectinib, brigatinib, crizotinib) as first-line therapy for patients with ALK rearrangements 7

REFERENCES

6

non-small cell lung cancer, version 2.2013. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2013